BMO Capital analyst Kostas Biliouris has maintained their bullish stance on VERV stock, giving a Buy rating today.
Kostas Biliouris has given his Buy rating due to a combination of factors that highlight Verve Therapeutics’ potential in the gene editing space, particularly with their VERVE-102 program. The encouraging safety profile of VERVE-102, with no significant adverse events reported, sets a strong foundation for its anticipated efficacy in lowering LDL-C levels by 40-50%, which is a significant benchmark. The upcoming data readout in the second quarter of 2025 is expected to be a major catalyst, potentially moving the stock by 50-100%.
Additionally, a potential opt-in decision by Eli Lilly in the latter half of 2025 is seen as a critical catalyst that could further elevate Verve’s market position and influence in the gene editing sector. The company’s strong cash position, extending its financial runway into mid-2027, and its strategic management team further bolster confidence in its long-term prospects. These elements collectively support the Buy rating, reflecting optimism about Verve’s innovative approach and market opportunities.